Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Patient Who Wouldn't Be Here Without Axcan's Photofrin Should Disappear Now, FDA Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Web videos featuring overblown patient testimonials prove an easy target for DDMAC.
Advertisement

Related Content

DDMAC Numb To Purported Advantages Of Dental Anesthetic
DDMAC Numb To Purported Advantages Of Dental Anesthetic
Luvox CR Symptom Benefit Claims Draw DDMAC Warning
Pfizer’s “Viva Viagra” Ad Skips A Beat On Safety Risks; FDA Issues Warning Letter
Axcan Photofrin approval

Topics

Advertisement
UsernamePublicRestriction

Register

PS071102

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel